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Pathological angiogenesis contributes to
tumour progression as well as to chronic
inflammatory diseases. In this issue of
EMBO Molecular Medicine, Esteban and
co-workers identify endothelial cell MT1-
MMP as a key regulator of intussusceptive
angiogenesis (IA) in inflammatory colitis.
Thrombospondin 1 (TSP1) cleavage by MT1-
MMP results in the binding of the c-terminal
fragment of TSP1 to avb3 integrin, which
induces nitric oxide (NO) production, vasodi-
lation and further initiation of IA. This novel
control mechanism of inflammatory IA
points towards promising new therapeutic
targets for inflammatory bowel disease.
EMBO Mol Med (2020) 12: e11663
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A ngiogenesis, the formation andgrowth of blood vessels, plays animportant role in normal develop-
ment and ischaemic diseases. Increasing
evidence supports the existence of different
mechanisms of blood vessel growth, includ-
ing sprouting and intussusceptive angiogen-
esis (IA). Both sprouting and IA occur under
normal physiological and pathological
conditions, including tumour growth (De
Spiegelaere et al, 2012).
Sprouting angiogenesis, where blood
vessel endothelial cells locally proliferate,
bud and form branching vessels off a main
vessel, is an invasive process initiated by
multiple matrix metalloproteinases (MMPs).
These enzymes degrade extracellular matrix
proteins, allowing vascular endothelial cells
to invade the tissue and generate vessel
sprouts. In contrast, IA is the expansion of
the microvasculature through the formation
of intraluminal pillars via invagination of
the vessel wall into the vascular lumen, ulti-
mately resulting in vessel “splitting”. Blood
flow dynamics appear to be crucial in shap-
ing this process, and neither pillar formation
nor IA itself appear to be invasive processes
(Paku et al, 2011). However, little is known
about the cellular and molecular control of
IA, highlighting the need for improved
in vivo and in vitro models (De Spiegelaere
et al, 2012).
Sprouting angiogenesis often precedes IA,
especially in the tumour setting (Karthik
et al, 2018). Importantly, since IA is stimu-
lated after initiation of anti-angiogenic ther-
apy, it constitutes an alternative target to
combat vascular disease or resistance to
anti-angiogenic therapy.
In this issue of EMBO Molecular Medi-
cine, Esteban et al report a previously
unrecognised role for endothelial MT1-MMP
in IA (Esteban et al, 2020). The expression
of the membrane protease MMP family
member MT1-MMP, also known as MMP-
14, is upregulated in angiogenesis and in
inflammatory diseases; however, its poten-
tial implications in either IA or colitis were
unknown.
Here, in a DSS-induced model of colitis,
mice lacking endothelial cell-MT1-MMP had
reduced number of IA capillary events,
resulting in ameliorating colitis symptoms.
Using a new whole-mount imaging method
to overcome previous limitations in identify-
ing and analysing IA (Hlushchuk et al, 2011;
Nowak-Sliwinska et al, 2018), the authors
showed that MT1-MMP expression levels
were separately controlled in arterioles and
capillaries, leading to a novel bimodal role of
action for this enzyme. Constitutive MT1-
MMP expression in arterioles drove NO
production, increasing blood flow in the
downstream capillary plexus. However, in
the capillary y-junctions, DSS-induced upreg-
ulation of MT1-MMP drove NO production,
which led to endothelial cell remodelling and
pillar formation. Although not confirmed in
the current study, the authors previously
showed that NO regulates MT1-MMP activity
during endothelial cell migration, therefore
suggesting that, by a positive feed-back loop,
NO could further reinforce MT1-MMP upreg-
ulation (Genis et al, 2007).
Moreover, by combining a Cleavpredict
search with in silico protein modelling, the
authors identified that MT1-MMP drives
TSP1 cleavage, allowing c-terminal TSP1
fragment release and interaction with CD47/
avb3 integrin in the induction of NO during
IA (Fig 1). This elegant in silico analysis
could potentially be expanded to aid identifi-
cation of novel substrates and the subse-
quent development of cell-specific strategies.
Targeting avb3 integrin has been exten-
sively studied in angiogenesis (Robinson &
Hodivala-Dilke, 2011), and some inhibitors
such as the RGD-mimetic Cilengitide under-
went clinical trials for cancer treatment.
Unfortunately, Cilengitide did not meet the
primary endpoints and therefore failed in
randomised clinical trials (Demircioglu &
Hodivala-Dilke, 2016). This present study
suggests that specifically targeting avb3-TSP1-
c-terminal fragment interactions may allow IA
targeting. Another important finding of this
study is the proposed use of serum cleaved
TSP-1 as a biomarker of ulcerative colitis or
related Crohn’s disease. TSP-1 was proposed
as a biomarker in different pathologies such
as pulmonary hypertension and other
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cardiovascular diseases, and it would be inter-
esting to investigate whether it could be
further used as a biomarker in cancers that
undergo IA and could benefit from anti-IA
rather than anti-angiogenic therapies.
While the clinical and translational appli-
cations of this work remain to be estab-
lished, the present results from Arroyo’s
laboratory (summarised in Fig 1) provide
exciting new opportunities for inflammatory
disease control via the specific regulation of
IA. All the players in this exquisitely
balanced pathway of MT1-MMP-TSP1-avb3
have been therapeutic targets in the past,
suggesting that drug repurposing may be of
value in this context. But should we
consider endothelial-specific MT1-MMP
genetic editing as a real option for improved
colitis control? Only the future will tell.
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Figure 1. Schematic representation of the proposed model by Esteban et al (2020).
Endothelial cell MT1-MMP cleaves TSP1 to generate c-terminal fragments of TSP1. These in turn bind avb3 integrin, leading to NO production. NO production induces
vasodilation in arterioles and initiates the process of intussusceptive remodelling. The process of pillar formation and vascular splitting reduces the blood flow in inflamed
intestinal mucosa. Targeting this pathway would help control colitis symptoms.
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